ESKATA (nda209305)- (40%)

Generic Name	HYDROGEN PEROXIDE	Innovator	ACLARIS
Dosage	40%
ParaIV Filing	No	505(b)2 Filing	Yes
Last Patent Expiry	2035-Jul-04	NCE Excl Expiry	Expired
ODE Expiry	None	NP Expiry	2020-Dec-14
GAIN Expiry	None	Drug Complexity	No
Indication	ESKATA is indicated for the treatment of seborrheic keratoses that are raised.

Approvals and Launches

Final Approvals	Tentative Approvals	Generic Launches
0	0	0

Other Developers

Total Other Developers	None

Drugs with Suitability

Drugs with Suitability	No

Drug Pricing

	NDA			ANDA
Dosage	Weekly	Monthly	Yearly	Yearly Up	Yearly Down
40%	**	**	-	-	-

Drug Sales

NDA Sales Available	Total Generic Sales Available
No	0

Manufacturing Details of ESKATA